DK2264009T3 - Pyridylaminoeddikesyreforbindelse - Google Patents

Pyridylaminoeddikesyreforbindelse Download PDF

Info

Publication number
DK2264009T3
DK2264009T3 DK09721163.5T DK09721163T DK2264009T3 DK 2264009 T3 DK2264009 T3 DK 2264009T3 DK 09721163 T DK09721163 T DK 09721163T DK 2264009 T3 DK2264009 T3 DK 2264009T3
Authority
DK
Denmark
Prior art keywords
pyridin
group
compound
aminomethyl
ylsulfonyl
Prior art date
Application number
DK09721163.5T
Other languages
English (en)
Inventor
Ryo Iwamura
Masayuki Tanaka
Tetsushi Katsube
Manabu Shigetomi
Eiji Okanari
Yasunori Tokunaga
Hiroshi Fujiwara
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41065261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2264009(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ube Industries filed Critical Ube Industries
Application granted granted Critical
Publication of DK2264009T3 publication Critical patent/DK2264009T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (4)

1. Pyridylaminoeddikesyreforbindelse repræsenteret af formlen (1):
hvor R1 repræsenterer et hydrogenatom, en methylgruppe, en ethylgruppe, en isopropylgruppe eller en hexylgruppe, R2 og R3 begge representerer hydrogenatomer, Y repræsenterer en benzofuran-2-yl-gruppe, en benzo[b]thiophen-2-yl-gruppe, en 6-chlor-benzo[b]thiophen-2-yl-gruppe, en 6-methoxybenzo[b]thiophen-2-yl-gruppe, en biphenyl-4-yl-gruppe, en 4'-fluorbiphenyl-4-yl-gruppe, en 4'-chlorbiphenyl-4-yl-gruppe, en 4-(pyrazol- 1- yl)phenyl-gruppe, en 4-(thiazol-2-yl)phenyl-gruppe, en 4-(5-chlorthiazol- 2- yl)phenyl-gruppe, en 4-(5-methylthiazol-2-yl)phenyl-gruppe, en 4-(4,5-dimethylthiazol-2-yl)phenyl-gruppe, en 4-(4-trifluormethylthiazol-2-yl)phenyl-gruppe, en 4-(thiazol-4-yl)phenyl-gruppe, en 4-(l,2,4-triazol-l-yl)phenyl-gruppe, en 4-(pyridin-2-yl)phenyl-gruppe, en 4-(pyridazin-4-yl)-phenyl-gruppe, en 4-(pyrimidin-2-yl)phenyl-gruppe, en 4-(4,5-dihydrothiazol-2-yl)phenyl-gruppe eller en 6-phenylpyridazin-3-yl-gruppe og Z repræsenterer en phenylgruppe, en 2-fluorphenylgruppe, en 3-fluorphenylgruppe, en 4-fluorphenylgruppe, en 2-chlorphenylgruppe, en 3-chlorphenylgruppe, en 4-chlorphenylgruppe, en 2,6-dichlorphenylgruppe, en 4-methoxyphenylgruppe, en pyridin-2-yl-gruppe eller en pyridin-3-yl-gruppe, eller et farmakologisk acceptabelt salt deraf.
2. Pyridylaminoeddikesyreforbindelse eller farmakologisk acceptabelt salt deraf ifølge krav 1, hvor pyridylaminoeddikesyreforbindelsen er: {6-[(benzofuran-2-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2- ylamino}-eddikesyre,
{6-[(benzo[b]thiophen-2-ylmethyl)(pyridin-3- ylsulfonyl)aminomethyl]pyridin-2-yl-amino}eddikesyre, {6-[(6-chlorbenzo[b]thiophen-2-ylmethyl)(pyridin-3- ylsulfonyl)aminomethyl]pyridin-2-ylamino>eddikesyre, {6-[(6-methoxybenzo[b]thiophen-2-ylmethyl)(pyridin-3- ylsulfonyl)aminomethyl]-pyridin-2-ylamino}eddikesyre, { 6-[(biphenyl-4-ylmethyl)(pyridin-2-ylsulfonyl)aminomethyl]pyridin-2-ylamino>eddikesyre, {6-[(biphenyl-4-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2- ylamino}eddikesyre, {6-[(4'-fluorbiphenyl-4-ylmethyl)(pyridin-3- ylsulfonyl)aminomethyl]pyridin-2-yl-amino>eddikesyre, {6-[(4'-chlorbiphenyl-4-ylmethyl)(pyridin-3- ylsulfonyl)aminomethyl]pyridin-2-yl-amino>eddikesyre, (6-{(4-fluorbenzensulfonyl)[4-(pyrazol-l-yl)benzyl]aminomethyl>pyridin-2- yl-amino)eddikesyre, (6-{[4-(pyrazol-l-yl)benzyl](pyridin-2-ylsulfonyl)aminomethyl>pyridin-2- ylamino)eddikesyre, (6-{[4-(pyrazol-l-yl)benzyl](pyndin-3-ylsulfonyl)aminomethyl>pyridin-2- ylamino)-eddikesyre, isopropyl-(6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2- yl)benzyl]aminomethyl}pyridin-2-ylamino)acetat, ethyl(6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl>pyridin- 2-yl-amino)acetat, (6-{(4-fluorbenzensulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl>pyridin-2- ylamino)-eddikesyre, (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl>pyridin-2- ylamino)-eddikesyre, (6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl>pyridin-2- ylamino)-eddikesyre, (6-{(pyridin-2-ylsulfonyl)[4-(4-trifluormethylthiazol-2- yl)benzyl]aminomethyl>-pyridin-2-ylamino)eddikesyre, (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-4-yl)benzyl]aminomethyl>pyridin-2- ylamino)-eddikesyre, (6-{ [4-(pyridin-2-yl)benzyl] (pyrid in-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)-eddikesyre, (6-{[4-(pyridazin-4-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2- ylamino)-eddikesyre, (6-{(pyridin-2-ylsulfonyl)[4-(pyrimidin-2-yl)benzyl]aminomethyl>pyridin-2- ylamino)-eddikesyre, (6-{[4-(4,5-dihydrothiazol-2-yl)benzyl](4- fluorbenzensulfonyl)aminomethyl>pyridin-2-ylamino)eddikesyre, {6-[(6-phenylpyridazin-3-ylmethyl)(pyridin-3- ylsulfonyl)aminomethyl]pyridin-2-yl-amino>eddikesyre, hexyl(6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2- yl)benzyl]aminomethyl>pyridin-2-yl-amino)acetat, (6-{[4-(5-chlorthiazol-2-yl)benzyl](pyridin-2- ylsulfonyl)aminomethyl>pyridin-2-yl-amino)eddikesyre, (6-{[4-(5-methylthiazol-2-yl)benzyl](pyridin-2- ylsulfonyl)aminomethyl}pyridin-2-yl-amino)eddikesyre, (6-{[4-(4,5-dimethylthiazol-2-yl)benzyl](pyridin-2- ylsulfonyl)aminomethyl}pyridin-2-ylamino)eddikesyre, (6-{(pyridin-3-ylsulfonyl)[4-(l,2,4-triazol-l- yl)benzyl]aminomethyl}pyridin-2-yl-amino)eddikesyre, ethyl (6-{[4-(pyrazol-l-yl)benzyl](pyridin-3- ylsulfonyl)aminomethyl>pyridin-2-yl-amino)acetat, eller isopropyl(6-{[4-(pyrazol-l-yl)benzyl](pyridin-3- ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetat.
3. Farmaceutisk sammensætning omfattende pyridylaminoeddikesyreforbindelsen ifølge krav 1 eller 2 eller et farmakologisk acceptablet salt deraf som en aktiv ingrediens.
4. Farmaceutisk sammensætning ifølge krav 3 til at forhindre eller behandle en luftvejssygdom.
DK09721163.5T 2008-03-12 2009-03-12 Pyridylaminoeddikesyreforbindelse DK2264009T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008062926 2008-03-12
PCT/JP2009/054713 WO2009113600A1 (ja) 2008-03-12 2009-03-12 ピリジルアミノ酢酸化合物

Publications (1)

Publication Number Publication Date
DK2264009T3 true DK2264009T3 (da) 2019-04-15

Family

ID=41065261

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09721163.5T DK2264009T3 (da) 2008-03-12 2009-03-12 Pyridylaminoeddikesyreforbindelse

Country Status (18)

Country Link
US (2) US8648097B2 (da)
EP (1) EP2264009B1 (da)
JP (3) JP5136640B2 (da)
KR (1) KR101609001B1 (da)
CN (2) CN103965099A (da)
AU (1) AU2009224329B2 (da)
CA (1) CA2718393C (da)
CY (1) CY1121543T1 (da)
DK (1) DK2264009T3 (da)
ES (1) ES2718813T3 (da)
HR (1) HRP20190509T1 (da)
HU (1) HUE042839T2 (da)
LT (1) LT2264009T (da)
PL (1) PL2264009T3 (da)
PT (1) PT2264009T (da)
SI (1) SI2264009T1 (da)
TR (1) TR201904655T4 (da)
WO (1) WO2009113600A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190509T1 (hr) 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) * 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
US20120226036A1 (en) * 2009-09-11 2012-09-06 Ube Industries, Ltd. Substituted carbonyl compound
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
EP2476668B1 (en) * 2009-09-11 2013-11-06 Ube Industries, Ltd. Aniline compounds
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
CN102666490A (zh) * 2009-12-25 2012-09-12 宇部兴产株式会社 氨基吡啶化合物
AU2011225122B8 (en) * 2010-03-12 2013-12-12 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
JP2013522274A (ja) 2010-03-18 2013-06-13 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 非生物的な植物ストレスに対する活性剤としてのアリールスルホンアミド類及びヘタリールスルホンアミド類
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
HK1219103A1 (en) 2013-03-28 2017-03-24 Ube Industries, Ltd. Substituted biaryl compound
CA2923016A1 (en) * 2013-09-02 2015-03-05 Ube Industries, Ltd. Pharmaceutical composition for treatment and/or prevention of pulmonary disease
EP3093018B1 (en) 2014-01-10 2018-11-28 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
KR101858373B1 (ko) * 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
CA2935055C (en) 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
US10519112B2 (en) 2014-06-10 2019-12-31 Ube Industries, Ltd. Method for producing heteroaromatic sulfonamide compound
US10774072B2 (en) * 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
KR20170013994A (ko) 2014-06-10 2017-02-07 우베 고산 가부시키가이샤 N-치환 술폰아미드 화합물 및 그의 제조 방법
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
US20180200239A1 (en) 2015-07-09 2018-07-19 Santen Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
WO2018108627A1 (de) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen
WO2019025153A1 (de) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft Verwendung von substituierten n-sulfonyl-n'-aryldiaminoalkanen und n-sulfonyl-n'-heteroaryldiaminoalkanen oder deren salzen zur steigerung der stresstoleranz in pflanzen
WO2019065838A1 (ja) 2017-09-29 2019-04-04 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
CA3086445A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Omidenepag combination
CN111526876A (zh) 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
CN118084895B (zh) * 2024-02-28 2025-09-05 中国药科大学 一种一氧化氮供体型Omidenepag衍生物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509211A (ja) 1990-06-08 1994-10-13 エスピーエス・テクノロジーズ・インコーポレーテッド 改良磁性材料及びその製造方法
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
TR200002182T2 (tr) 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
CN101284773A (zh) * 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
JP2005507413A (ja) 2001-10-26 2005-03-17 アラーガン　インコーポレイテッド ＥＰ２−受容体作用薬としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似物
PY0300568A (es) * 2002-01-31 2004-10-01 Pfizer Prod Inc Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico
AU2003211574A1 (en) 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
CA2518193A1 (en) * 2003-03-04 2004-09-16 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
GB0329620D0 (en) 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
JP2007186424A (ja) 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
WO2005072743A1 (ja) 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
US7994196B2 (en) 2004-02-12 2011-08-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
WO2006009876A2 (en) 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
BRPI0606644A2 (pt) 2005-01-14 2009-07-14 Hoffmann La Roche derivados de 4-carboxamida tiazola
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd A PYRIDINE DERIVATIVE ANTIPILIC AGENT
EP1912957A4 (en) 2005-08-03 2009-05-13 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
CA2618486A1 (en) * 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
CN101495452B (zh) * 2006-07-28 2012-04-25 辉瑞产品公司 Ep2激动剂
HRP20190509T1 (hr) 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma

Also Published As

Publication number Publication date
EP2264009B1 (en) 2019-03-06
US20140113907A1 (en) 2014-04-24
JP2014177476A (ja) 2014-09-25
LT2264009T (lt) 2019-04-25
CY1121543T1 (el) 2020-05-29
JP5136640B2 (ja) 2013-02-06
KR101609001B1 (ko) 2016-04-04
AU2009224329A1 (en) 2009-09-17
US20110054172A1 (en) 2011-03-03
WO2009113600A1 (ja) 2009-09-17
HRP20190509T1 (hr) 2019-05-03
JPWO2009113600A1 (ja) 2011-07-21
CN101970410B (zh) 2014-06-25
HUE042839T2 (hu) 2019-07-29
JP2013063994A (ja) 2013-04-11
EP2264009A4 (en) 2012-08-01
SI2264009T1 (sl) 2019-05-31
KR20100123903A (ko) 2010-11-25
ES2718813T3 (es) 2019-07-04
CA2718393A1 (en) 2009-09-17
EP2264009A1 (en) 2010-12-22
CA2718393C (en) 2015-06-16
CN103965099A (zh) 2014-08-06
US8648097B2 (en) 2014-02-11
PT2264009T (pt) 2019-04-29
TR201904655T4 (tr) 2019-06-21
JP5545344B2 (ja) 2014-07-09
PL2264009T3 (pl) 2019-07-31
AU2009224329B2 (en) 2013-11-07
CN101970410A (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
DK2264009T3 (da) Pyridylaminoeddikesyreforbindelse
DK2415763T3 (da) Farmaceutisk sammensætning til behandling eller forebyggelse af glaukom
TWI536991B (zh) 黏著斑激酶之抑制劑
JP2021519263A (ja) 化合物及びその使用
JP4767975B2 (ja) ｍＧｌｕＲ５アンタゴニストとしてのピリジン−２−カルボキサミド誘導体
JP2011057633A (ja) ピリジルアミノ酢酸化合物を含有する医薬
TW202412773A (zh) 雜芳基衍生化合物及其用途
HK1167139A (en) Pharmaceutical composition for treating or preventing glaucoma
HK1170490B (en) Pharmaceutical composition for treating or preventing glaucoma